Virtu Financial LLC Acquires New Position in Elevation Oncology, Inc. (NASDAQ:ELEV)

Virtu Financial LLC bought a new position in shares of Elevation Oncology, Inc. ( NASDAQ:ELEV – Free Report ) during the fourth quarter, HoldingsChannel.com reports.

The firm bought 63,974 shares of the company’s stock, valued at approximately $36,000. Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its position in shares of Elevation Oncology by 33.



9% during the fourth quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock worth $35,000 after acquiring an additional 15,560 shares during the period. JPMorgan Chase & Co.

grew its stake in Elevation Oncology by 175.9% during the 3rd quarter. JPMorgan Chase & Co.

now owns 61,334 shares of the company’s stock worth $37,000 after purchasing an additional 39,101 shares in the last quarter. Palumbo Wealth Management LLC increased its holdings in Elevation Oncology by 294.5% during the 4th quarter.

Palumbo Wealth Management LLC now owns 69,105 shares of the company’s stock worth $39,000 after purchasing an additional 51,590 shares during the period. Barclays PLC raised its position in Elevation Oncology by 302.4% in the 3rd quarter.

Barclays PLC now owns 72,077 shares of the company’s stock valued at $43,000 after purchasing an additional 54,167 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Elevation Oncology by 13.5% in the 3rd quarter.

State Street Corp now owns 1,018,026 shares of the company’s stock valued at $611,000 after buying an additional 120,993 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades Several brokerages recently weighed in on ELEV. Leerink Partnrs cut shares of Elevation Oncology from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 20th. Leerink Partners cut shares of Elevation Oncology from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $9.

00 to $1.00 in a research report on Friday, March 21st. JMP Securities reissued a “market outperform” rating and issued a $7.

00 target price on shares of Elevation Oncology in a report on Thursday, December 19th. HC Wainwright cut their target price on Elevation Oncology from $6.00 to $1.

00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, Wedbush lowered shares of Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 20th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company.

Based on data from MarketBeat, Elevation Oncology currently has an average rating of “Hold” and an average target price of $3.39. Elevation Oncology Stock Down 4.

5 % Shares of Elevation Oncology stock opened at $0.25 on Wednesday. Elevation Oncology, Inc.

has a one year low of $0.24 and a one year high of $5.83.

The company has a debt-to-equity ratio of 0.45, a quick ratio of 17.77 and a current ratio of 17.

77. The firm has a fifty day moving average of $0.53 and a two-hundred day moving average of $0.

58. The company has a market cap of $14.66 million, a P/E ratio of -0.

30 and a beta of 1.37. Elevation Oncology ( NASDAQ:ELEV – Get Free Report ) last announced its quarterly earnings data on Thursday, March 6th.

The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.

04. On average, analysts forecast that Elevation Oncology, Inc. will post -0.

84 earnings per share for the current year. Elevation Oncology Profile ( Free Report ) Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.

2, a clinically validated molecular target. Featured Stories Want to see what other hedge funds are holding ELEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevation Oncology, Inc.

( NASDAQ:ELEV – Free Report ). Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter .

.